- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01477359
Coorte Prospectiva Multicêntrica de Sarcoidose Cardíaca (CHASM-CS)
Estudo de Coorte Prospectivo Multicêntrico de Sarcoidose Cardíaca
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.
There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.
A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
Visão geral do estudo
Status
Condições
Descrição detalhada
Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).
Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.
Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.
All patients will be followed until the last patient recruited has been followed for 4 years.
The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.
There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.
The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Janine E Ryan, BA(H), CCRP
- Número de telefone: 17077 613-696-7000
- E-mail: jryan@ottawaheart.ca
Estude backup de contato
- Nome: David Birnie, MD
- Número de telefone: 613-696-7269
- E-mail: dbirnie@ottawaheart.ca
Locais de estudo
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 2T9
- Recrutamento
- Libin Cardiovascular Institute of Alberta
-
Investigador principal:
- Russell Quinn, MD
-
Contato:
- Russell Quinn, MD
-
Edmonton, Alberta, Canadá, T6G 2B7
- Recrutamento
- University of Alberta Hospital
-
Contato:
- Tomascz Hruczkowski, MD
-
Investigador principal:
- Tomascz Hruczkowski, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Recrutamento
- St. Paul's Hospital
-
Contato:
- Shanta Chakrabarti, MD
-
Investigador principal:
- Shanta Chakrabarti, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 3A7
- Recrutamento
- QEII Health Sciences Center
-
Investigador principal:
- Ciorsti MacIntyre, MD
-
Contato:
- Kim Anderson, MD
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 2X2
- Recrutamento
- Hamilton Health Sciences Centre
-
Investigador principal:
- Jeff Healey, MD
-
Contato:
- Gerard Cox, MD
-
Contato:
- Jeff Healey, MD
-
London, Ontario, Canadá, N6A 5A5
- Recrutamento
- London Health Sciences Centre
-
Contato:
- Lorne Gula, MD
-
Investigador principal:
- Lorne Gula, MD
-
Newmarket, Ontario, Canadá, L3Y 2P9
- Recrutamento
- Southlake Regional Health Centre
-
Contato:
- Bernice Tsang, MD
-
Investigador principal:
- Bernice Tsang, MD
-
Ottawa, Ontario, Canadá, K1Y 4W7
- Recrutamento
- University of Ottawa Heart Institute
-
Contato:
- Tammy Knight
- Número de telefone: 19080 613-696-7000
- E-mail: tknight@ottawaheart.ca
-
Investigador principal:
- David Birnie, MD
-
Contato:
- Janine E Ryan, BA H
- Número de telefone: 17077 613-696-7000
- E-mail: jryan@ottawaheart.ca
-
Toronto, Ontario, Canadá, M5G 2C4
- Recrutamento
- Toronto General Hospital
-
Contato:
- Andrew Ha, MD
-
Investigador principal:
- Andrew Ha, MD
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T 1C8
- Recrutamento
- Montreal Heart Institute
-
Contato:
- Lena Rivard, MD
-
Investigador principal:
- Lena Rivard, MD
-
Montreal, Quebec, Canadá, H3G 1A4
- Recrutamento
- McGill University Health Centre
-
Contato:
- Fiorella Rafti
-
Investigador principal:
- Martin L Bernier, MD
-
Montreal, Quebec, Canadá, H2W 1T8
- Ainda não está recrutando
- Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
-
Contato:
- Julie Fleury, RN
-
Investigador principal:
- Benoit Coutu, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Canadá, S4P 0W5
- Recrutamento
- Prairie Vascular Research Inc-Regina General Hospital
-
Contato:
- Kendra Townsend
- E-mail: Ktownsend.pvri@gmail.com
-
Investigador principal:
- Andrea Lavoie, MD
-
-
-
-
-
Sapporo, Japão, 060-8638
- Recrutamento
- Hokkaido University
-
Contato:
- Ichizo Tsujino, MD
- Número de telefone: 81-11-706-5911
- E-mail: itsujino@med.hokudai.ac.jp
-
Investigador principal:
- Ichizo Tsujino, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Electrophysiology Service patients
Descrição
Inclusion Criteria:
To diagnose Clinically Manifest CS all following criteria must be met:
(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS
To diagnose clinically silent CS all of the following criteria must be met
(i) Biopsy proven extra-cardiac sarcoidosis
AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis
AND (iii) CMR suggestive of cardiac sarcoidosis
AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)
Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control
Exclusion Criteria:
- unable or unwilling to provide informed consent
- patients who are pregnant or lactating
- patients with known claustrophobia
- age < 18 years
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
CS screened as underlying etiology
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Primary Outcome for ALL Patients
Prazo: Through study completion, on average 10 years
|
The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation. Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure. Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Secondary Outcomes for ALL Patients
Prazo: Through study completion, on average 10 years
|
1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for ALL Patients
Prazo: Through study completion, on average 10 years
|
2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Prazo: Through study completion, on average 10 years
|
8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Prazo: Through study completion, on average 10 years
|
1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
- Investigador principal: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
- Investigador principal: David Birnie, MD, Ottawa Heart Institute Research Corporation
Publicações e links úteis
Publicações Gerais
- Weng W, Wiefels C, Chakrabarti S, Nery PB, Celiker-Guler E, Healey JS, Hruczkowski TW, Quinn FR, Promislow S, Medor MC, Spence S, Odabashian R, Alqarawi W, Juneau D, de Kemp R, Leung E, Beanlands R, Birnie D. Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. J Am Heart Assoc. 2020 Sep;9(17):e017086. doi: 10.1161/JAHA.120.017086. Epub 2020 Aug 20.
- Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, Beanlands R, Birnie D. Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: A Prospective Pilot Study. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2280-2281. doi: 10.1016/j.jcmg.2019.06.020. Epub 2019 Aug 14. No abstract available.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UOHI-04
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .